Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Virology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Vaccines and Antiviral Agents

Induction of Broadly Reactive Anti-Hemagglutinin Stalk Antibodies by an H5N1 Vaccine in Humans

Raffael Nachbagauer, Teddy John Wohlbold, Ariana Hirsh, Rong Hai, Haakon Sjursen, Peter Palese, Rebecca J. Cox, Florian Krammer
D. S. Lyles, Editor
Raffael Nachbagauer
aDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
hFaculty of Life Sciences, University of Vienna, Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Teddy John Wohlbold
aDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
bGraduate School of Biological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ariana Hirsh
aDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rong Hai
aDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haakon Sjursen
cThe Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway
dSection for Infectious Diseases, Medical Department, Haukeland University Hospital, Bergen, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Palese
aDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
eDepartment of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rebecca J. Cox
cThe Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway
fJebsen Centre for Influenza Vaccine Research, Department of Clinical Science, University of Bergen, Bergen, Norway
gDepartment of Research and Development, Haukeland University Hospital, Bergen, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Florian Krammer
aDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. S. Lyles
Roles: Editor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/JVI.02133-14
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • FIG 1
    • Open in new tab
    • Download powerpoint
    FIG 1

    H5N1 vaccination induces stalk-reactive antibodies in humans. (A) Study design. Participants received the H5N1 vaccine intramuscularly on day 0 and day 21. Blood was drawn on days 0, 21, and 42 postpriming, as well as after 6 and 12 months. (B) Stalk-reactive antibodies were measured in a cH6/1 ELISA. Reciprocal geometric mean titers on day 0 were detected at 1:2,722 and showed a high, significant increase for day 21 (1:1,1943; P < 0.0001) and day 42 (1:15,267; P < 0.0001). The levels of stalk-reactive antibodies declined after 6 months (1:4,143; P = 0.032) and remained at a similar level up to 12 months postvaccination (1:4,087; P = 0.0051), still significantly higher than baseline titers. (C) Induction of stalk-reactive antibodies over baseline. Stalk-reactive antibody titers showed a 4.4-fold induction over baseline after the first round of vaccination, with a further boost to 5.6-fold after the second round. After 6 months, the stalk-reactive antibodies declined to a level of 1.5-fold over baseline and were retained at that level for up to 12 months (1.6-fold). (D) Induction of stalk-reactive antibodies for individual vaccine groups. There was no statistical significant difference in induction of stalk-reactive antibodies for the various HA contents of the vaccines, as well as adjuvant, for any time point (21 days, P = 0.3391; 42 days, P = 0.6267; 6 months, P = 0.3068; 12 months, P = 0.9807). (E) Biological activity of stalk-reactive antibodies was measured in a microneutralization assay with a cH9/1 N3 virus. Using an HA head domain and neuraminidase to which humans are naive ensured measurement of stalk-reactive antibodies only. Baseline titers were relatively high, at 1:569, but showed a significant increase 42 days postpriming, to 1:1,092 (P < 0.0001). (F) Correlation of stalk-reactive antibodies measured by ELISA and microneutralization assay. The levels of stalk-reactive antibodies measured by ELISA significantly correlated with their measured neutralizing ability in vitro (Spearman r = 0.5225; P < 0.0001). n.s., not significant. In Fig. 1 to 4, * indicates a P value of ≤0.05, ** indicates a P value of ≤0.01, and *** indicates a P value of ≤0.001.

  • FIG 2
    • Open in new tab
    • Download powerpoint
    FIG 2

    H5N1 vaccination induces cross-reactive group 1 HA antibodies in humans. (A) Titers of antibody against group 1 HAs H2 and H18 and group 2 HA H3 were measured on day 0 and day 42 postpriming. Titers of antibody against H2 increased from 1:1,118 to 1:4,095 (P < 0.0001) and titers of antibody against H18 from 1:791 to 1:2,024 (P < 0.0001). Titers of antibody against H3 remained at similar levels, 1:2,186 and 1:2,599 (P = 0.66). (B) Induction over baseline of antibodies against group 1 HAs H2 and H18 and group 2 HA H3 was calculated for day 42 postpriming. Antibodies against H2 show a 3.6-fold induction over baseline and induction of antibodies against H18 was 2.5-fold, confirming group cross-reactivity for group 1 HAs. Cross-group antibodies against H3 showed only a low induction, at 1.19-fold over baseline. (C) Correlation of stalk-reactive and H2 cross-reactive antibodies. Antibodies against the HA stalk domain and H2 showed a significant positive correlation (Spearman r = 0.5656; P < 0.0001). This indicates that the cross-reactivity is mostly caused by antibodies against shared epitopes in the stalk domain. All samples were analyzed, and overlapping results are presented as single points.

  • FIG 3
    • Open in new tab
    • Download powerpoint
    FIG 3

    H5N1 vaccination elicits a weak antibody response against NA in humans. (A) Titers of antibody against homologous N1 (A/Vietnam/1203/2004 [VN]) and heterologous N1 (A/California/04/2009 [Cal09]) were measured on day 0 and day 42 postpriming. Titers of antibody against VN N1 increased slightly, from 1:755 to 1:1,131 (P = 0.0031), but the increase for Cal09 N1 from 1:1,817 to 1:2,072 was not significant (P = 0.7231). (B) Induction over baseline of antibodies against homologous N1 (VN) and heterologous N1 (Cal09) was calculated for day 42 postpriming. The induction for VN N1 was 1.5-fold over baseline, while induction for Cal09 N1 was only 1.1-fold.

  • FIG 4
    • Open in new tab
    • Download powerpoint
    FIG 4

    Protective activity of stalk-reactive antibodies. (A) All participants with an 8-fold or higher induction (n = 27) of stalk-reactive antibody titers 42 days postpriming were selected. Their day 0 and day 42 sera were pooled and intraperitoneally injected into mice. After 2 h, mice were challenged intranasally with cH9/1 N3 virus. Lungs of 5 mice for each group were harvested 3 days and 6 days after challenge. (B) An ELISA against the H9 head domain confirmed that there was no significant increase in antibodies against the H9 head domain 42 days postpriming (1:1,131 on day 0 versus 1:1,275 on day 42; P = 0.4901). (C) Virus titers in the lung were assessed in a plaque assay 3 days and 6 days postchallenge. Virus titers in the lungs of mice that received postvaccination sera were significantly lower on day 3 postchallenge (9.6-fold difference; P = 0.0036). On day 6 after virus challenge, 3 of the mice that received postvaccination sera had lung virus titers below the detection limit of 10 PFU per ml; the other 2 showed titers of 0.5 × 102, which was significantly lower than the mean titer of 1.3 × 104 for the mice that received prevaccination sera (P = 0.0243). (D) Mice that received postvaccination sera had significantly lower weight loss 3 days postchallenge (1.6% versus 3.7% weight loss; P = 0.0144) and even regained weight 6 days postchallenge, while mice that received prevaccination sera continued to lose weight (4.6% weight loss). (E) The neutralizing activity of stalk-reactive antibodies for the sera used in the passive-transfer experiment was assessed in a cH9/1 N3 microneutralization assay. The titer 42 days postpriming was significantly higher, at 1:1,225, than that on day 0, 1:582 (P = 0.0022).

  • FIG 5
    • Open in new tab
    • Download powerpoint
    FIG 5

    Model for induction of stalk-reactive antibodies by sequential exposure to HAs with conserved epitopes in the stalk but divergent globular head domains. Most humans had prior contact with H1 (A) and are therefore primed against the H1 stalk domain (dark green). The H5 (B) stalk domain (light green) shares conserved epitopes with the H1 stalk domain. This study shows that vaccination against H5N1 can boost antibodies against those shared epitopes. A vaccination strategy based on chimeric HAs (C) would combine an H1 stalk and an H5 head domain and might induce even higher titers of antibody against the HA stalk domain.

PreviousNext
Back to top
Download PDF
Citation Tools
Induction of Broadly Reactive Anti-Hemagglutinin Stalk Antibodies by an H5N1 Vaccine in Humans
Raffael Nachbagauer, Teddy John Wohlbold, Ariana Hirsh, Rong Hai, Haakon Sjursen, Peter Palese, Rebecca J. Cox, Florian Krammer
Journal of Virology Oct 2014, 88 (22) 13260-13268; DOI: 10.1128/JVI.02133-14

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Virology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Induction of Broadly Reactive Anti-Hemagglutinin Stalk Antibodies by an H5N1 Vaccine in Humans
(Your Name) has forwarded a page to you from Journal of Virology
(Your Name) thought you would be interested in this article in Journal of Virology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Induction of Broadly Reactive Anti-Hemagglutinin Stalk Antibodies by an H5N1 Vaccine in Humans
Raffael Nachbagauer, Teddy John Wohlbold, Ariana Hirsh, Rong Hai, Haakon Sjursen, Peter Palese, Rebecca J. Cox, Florian Krammer
Journal of Virology Oct 2014, 88 (22) 13260-13268; DOI: 10.1128/JVI.02133-14
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About JVI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #Jvirology

@ASMicrobiology

       

 

JVI in collaboration with

American Society for Virology

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0022-538X; Online ISSN: 1098-5514